Medicare Proposed Proton Therapy Payment Cuts
New CMS pricing rules could reduce payments to freestanding proton therapy centers by nearly 30 percent in 2027.
Updated on Oct. 9, 2026 in Cancer
Live Poll
Should Medicare reimbursement rates for specialized cancer therapy favor hospitals over local independent treatment centers?
The Centers for Medicare & Medicaid Services has proposed a national pricing methodology that would significantly decrease reimbursement rates for freestanding proton therapy centers. Lawmakers are now urging regulators to exclude these facilities from the planned 2027 reductions.
Why it matters
The proposed policy change aims to standardize payments across the country, but critics warn the sharp revenue decline could threaten the financial viability of specialized centers. This potential shift creates uncertainty for thousands of patients who rely on these high-cost facilities for advanced cancer care.
Proton therapy represents less than 2% of all radiation claims submitted to CMS, yet building a standalone facility requires an investment of up to $250 million. The proposal specifically impacts the 53 freestanding centers currently operating across the United States.
The players
Centers for Medicare & Medicaid Services
This federal agency within the U.S. Department of Health and Human Services manages Medicare, Medicaid, and the Children's Health Insurance Program.
UF Health Proton Therapy Institute
This facility provides specialized cancer treatments using proton therapy and has served 13,000 patients since its 2006 opening.
Ackerman Cancer Center
Established in 1997, this center expanded its services to include proton therapy in 2015.
Mayo Clinic
This non-profit academic medical center operates a campus in Jacksonville and has scheduled a 2027 expansion into proton therapy.
The details
CMS designed the proposal to replace localized payment systems managed by individual administrative contractors with a uniform national rate. However, members of Congress argue the methodology overlooks the specific resource-heavy nature of proton beam therapy and the financial risks it poses to independent providers.
Timeline
1997: Ackerman Cancer Center was founded.
2006: The UF Health Proton Therapy Institute opened.
September 28, 2026: Twenty-nine members of Congress wrote to the CMS Administrator to oppose the cuts.
November 1, 2026: A final CMS decision on the pricing proposal is due.
2027: The proposed payment changes are scheduled to take effect.
Health Landscape
The proposed pricing change represents an evolution of the CMS national methodology for payment standardization, which seeks to eliminate geographic variations in reimbursement. This move suggests a broader federal effort to consolidate healthcare payment structures across diverse facility types.
Patients currently receiving care at freestanding centers may face uncertainty regarding access or continued operations if their local facilities struggle with the funding cuts. Those seeking future treatment may also see fewer development projects if the financial environment deters hospitals from building new proton therapy units.
The takeaway
The conflict between federal cost-standardization goals and the high operational expenses of specialized medical facilities highlights the difficulty of funding cutting-edge cancer care. Readers should monitor their local health providers for updates on how these federal reimbursement changes might affect future facility operations and treatment availability.
Further reading
For more on evolving treatment standards, visit the Cancer section.
Source note: This article includes information reported by Florida Times-Union.
Live Poll
Should Medicare reimbursement rates for specialized cancer therapy favor hospitals over local independent treatment centers?
